NeuroBo Pharmaceuticals Inc logo

NeuroBo Pharmaceuticals Inc

$ 12.52 -0.82 (-6.15%) 08:08 PM EST
P/E:
At Loss
P/B:
1.24
Market Cap:
$ 11.13M
Enterprise V:
$ 3.01M
Volume:
169.47K
Avg Vol (2M):
800.17K
Volume:
169.47K
Market Cap $:
11.13M
PE Ratio:
At Loss
Avg Vol (2-Month):
800.17K
Enterprise Value $:
3.01M
PB Ratio:
1.24
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.88
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 43.4
3-Year EPS without NRI Growth Rate 43.5
3-Year FCF Growth Rate 42.2
Name Current Vs Industry Vs History
5-Day RSI 36.03
9-Day RSI 44.23
14-Day RSI 46.87
6-1 Month Momentum % -58.59
12-1 Month Momentum % -89.46

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.07
Quick Ratio 8.07
Cash Ratio 7.08

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -260.2
Name Current Vs Industry Vs History
ROE % -139.49
ROA % -120.2
ROIC % -5812.5
ROC (Joel Greenblatt) % -6205.44
ROCE % -138.18

Financials (Next Earnings Date:2022-11-15 Est.)

NRBO's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:NRBO

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -16.851
Beta -0.38
Volatility % 61.62
14-Day RSI 46.87
14-Day ATR ($) 5.0744
20-Day SMA ($) 14.99435
12-1 Month Momentum % -89.46
52-Week Range ($) 7.395 - 118.5
Shares Outstanding (Mil) 0.89

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

NeuroBo Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

NeuroBo Pharmaceuticals Inc Analysis

Share your research

Headlines

See More
No news.